Literature DB >> 29545341

Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience.

Morag Griffin1, Austin Kulasekararaj2, Sheyans Gandhi2, Talha Munir3, Stephen Richards3, Louise Arnold3, Nana Benson-Quarm2, Nicola Copeland3, Isabel Duggins2, Kathryn Riley3, Peter Hillmen3, Judith Marsh2, Anita Hill3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29545341      PMCID： PMC6068026          DOI： 10.3324/haematol.2017.183046

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Guidelines for the diagnosis and management of adult aplastic anaemia.

Authors:  Sally B Killick; Nick Bown; Jamie Cavenagh; Inderjeet Dokal; Theodora Foukaneli; Anita Hill; Peter Hillmen; Robin Ireland; Austin Kulasekararaj; Ghulam Mufti; John A Snowden; Sujith Samarasinghe; Anna Wood; Judith C W Marsh
Journal:  Br J Haematol       Date:  2015-11-16       Impact factor: 6.998

2.  Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party.

Authors:  J Marsh; H Schrezenmeier; P Marin; O Ilhan; P Ljungman; S McCann; G Socie; A Tichelli; J Passweg; J Hows; A Raghavachar; A Locasciulli; A Bacigalupo
Journal:  Blood       Date:  1999-04-01       Impact factor: 22.113

3.  Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis.

Authors:  S Pagliuca; A M Risitano; F S De Fontbrune; M Robin; A P Iori; S Marotta; D Michonneau; A Villate; D Desmier; G Socié; R P De Latour
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

4.  Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers.

Authors:  Nicolas Vallet; Flore Sicre de Fontbrune; Michaël Loschi; Deborah Desmier; Alban Villate; Fiorenza Barraco; Patrice Chevallier; Louis Terriou; Ibrahim Yakoub-Agha; Annalisa Ruggeri; Mohamad Mohty; Natacha Maillard; Pierre-Simon Rohrlich; Patrice Ceballos; Stéphanie Nguyen; Xavier Poiré; Gaëlle Guillerm; Reza Tabrizi; Jonathan Farhi; Raynier Devillier; Marie-Thérèse Rubio; Gérard Socié; Régis Peffault de Latour
Journal:  Haematologica       Date:  2017-12-21       Impact factor: 9.941

5.  Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.

Authors:  Chiharu Sugimori; Tatsuya Chuhjo; Xingmin Feng; Hirohito Yamazaki; Akiyoshi Takami; Masanao Teramura; Hideaki Mizoguchi; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

6.  Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria.

Authors:  Régis Peffault de Latour; Hubert Schrezenmeier; Andrea Bacigalupo; Didier Blaise; Carmino A de Souza; Stephane Vigouroux; Roelf Willemze; Louis Terriou; Andre Tichelli; Mohamad Mohty; Sophie de Guibert; Judith C Marsh; Jakob Passweg; Jean Yves Mary; Gerard Socié
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

7.  Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis.

Authors:  Andrea Bacigalupo; Gerard Socié; Rose Marie Hamladji; Mahmoud Aljurf; Alexei Maschan; Slawomira Kyrcz-Krzemien; Alicja Cybicka; Henrik Sengelov; Ali Unal; Dietrich Beelen; Anna Locasciulli; Carlo Dufour; Jakob R Passweg; Rosi Oneto; Alessio Signori; Judith C W Marsh
Journal:  Haematologica       Date:  2015-01-23       Impact factor: 9.941

8.  Effects of immunosuppressive therapy in a patient with aplastic anemia-paroxysmal nocturnal hemoglobinuria (AA-PNH) syndrome during ongoing eculizumab treatment.

Authors:  Jin Asano; Ryosuke Ueda; Yasuhiro Tanaka; Isaku Shinzato; Toshiro Takafuta
Journal:  Intern Med       Date:  2012-03-01       Impact factor: 1.271

9.  Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories.

Authors:  Régis Peffault de Latour; Jean Yves Mary; Célia Salanoubat; Louis Terriou; Gabriel Etienne; Mohamad Mohty; Sophie Roth; Sophie de Guibert; Sebastien Maury; Jean Yves Cahn; Gerard Socié
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

10.  Natural history of paroxysmal nocturnal hemoglobinuria.

Authors:  P Hillmen; S M Lewis; M Bessler; L Luzzatto; J V Dacie
Journal:  N Engl J Med       Date:  1995-11-09       Impact factor: 91.245
  10 in total
  4 in total

1.  Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment.

Authors:  Amy E DeZern; Richard J Jones; Robert A Brodsky
Journal:  Biol Blood Marrow Transplant       Date:  2018-07-26       Impact factor: 5.742

2.  Primary myelofibrosis with concurrent paroxysmal nocturnal haemoglobinuria presenting with erectile dysfunction.

Authors:  Zaenb Alsalman; Mortadah Alsalman; Mohammed Albesher; Alaa Alsalman; Sultan Saif; Ali Aldandan; Ahmed Alsuliman
Journal:  Oxf Med Case Reports       Date:  2022-05-23

Review 3.  Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.

Authors:  Antonio M Risitano; Serena Marotta; Patrizia Ricci; Luana Marano; Camilla Frieri; Fabiana Cacace; Michela Sica; Austin Kulasekararaj; Rodrigo T Calado; Phillip Scheinberg; Rosario Notaro; Regis Peffault de Latour
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

4.  Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study.

Authors:  Jamile Shammo; Ajeet Gajra; Yogesh Patel; Ioannis Tomazos; Jonathan Kish; Anita Hill; J Rafael Sierra; David Araten
Journal:  J Blood Med       Date:  2022-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.